MX2007005679A - Metodo para tratamiento de desordenes de movimiento. - Google Patents

Metodo para tratamiento de desordenes de movimiento.

Info

Publication number
MX2007005679A
MX2007005679A MX2007005679A MX2007005679A MX2007005679A MX 2007005679 A MX2007005679 A MX 2007005679A MX 2007005679 A MX2007005679 A MX 2007005679A MX 2007005679 A MX2007005679 A MX 2007005679A MX 2007005679 A MX2007005679 A MX 2007005679A
Authority
MX
Mexico
Prior art keywords
myoclonus
directed
compound
formula
movement disorders
Prior art date
Application number
MX2007005679A
Other languages
English (en)
Inventor
Steven Frucht
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MX2007005679A publication Critical patent/MX2007005679A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion esta dirigida a metodos para el tratamiento de desordenes de movimiento mediante el administrar una cantidad efectiva del compuesto de la formula (I) a los pacientes en necesidad del mismo. Mas particularmente, la invencion esta dirigida a un metodo para tratar mioclono incluyendo administrar a un paciente un compuesto de la formula (I) en donde el mioclono no es un mioclono esencial que responde al alcohol con distonia. En algunas incorporaciones, el mioclono es mioclono postipoxica. La invencion tambien esta dirigida a un metodo para tratar distonia, el temblor esencial, el temblor del cerebelo, un movimiento nervioso, corea, incluido administrar a un paciente un compuesto de la formula I.
MX2007005679A 2004-11-10 2005-11-09 Metodo para tratamiento de desordenes de movimiento. MX2007005679A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62664504P 2004-11-10 2004-11-10
PCT/US2005/040877 WO2006053186A2 (en) 2004-11-10 2005-11-09 Method for treatment of movement disorders

Publications (1)

Publication Number Publication Date
MX2007005679A true MX2007005679A (es) 2007-07-11

Family

ID=36337239

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005679A MX2007005679A (es) 2004-11-10 2005-11-09 Metodo para tratamiento de desordenes de movimiento.

Country Status (10)

Country Link
US (1) US20090137565A1 (es)
EP (1) EP1809286A4 (es)
JP (1) JP2008519847A (es)
KR (1) KR20070085838A (es)
CN (1) CN101098701A (es)
AU (1) AU2005304352A1 (es)
CA (1) CA2586975A1 (es)
IL (1) IL182906A0 (es)
MX (1) MX2007005679A (es)
WO (1) WO2006053186A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US8702629B2 (en) * 2005-03-17 2014-04-22 Great Lakes Neuro Technologies Inc. Movement disorder recovery system and method for continuous monitoring
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
CN101919811A (zh) * 2009-06-09 2010-12-22 北京博时安泰液体制剂科技有限公司 一种左乙拉西坦注射液及其制备方法
MX2020011961A (es) 2010-03-24 2022-04-19 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
AU2016328150B2 (en) 2015-09-23 2020-10-01 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
FR3049463B1 (fr) * 2016-04-01 2019-07-05 Debregeas Et Associes Pharma Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
EP3768251A4 (en) * 2018-03-22 2022-12-07 Research Foundation Of The City University Of New York MODULATION OF NEURAL NKCC1 AS A THERAPEUTIC STRATEGY FOR SPASTICISM AND RELATED DISORDERS
CN113395960A (zh) 2018-11-19 2021-09-14 爵士制药爱尔兰有限公司 抗酒精药物制剂
JP2022522270A (ja) 2019-03-01 2022-04-15 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
WO2021067457A1 (en) * 2019-09-30 2021-04-08 Massachusetts Eye And Ear Infirmary Objective evaluation of neurological movement disorders from medical imaging
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) * 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
JPS60168044A (ja) * 1984-02-10 1985-08-31 Sharp Corp 感湿素子
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4738985A (en) * 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US5990162A (en) * 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
ES2193777T3 (es) * 1998-12-23 2003-11-01 Orphan Medical Inc Disoluciones estables e inalterables microbiologicamente de sal de gamma-hidroxibutirato para el tratamiento de la narcolepsia.
EP1325014B1 (en) * 2000-09-22 2012-05-23 JPI Commercial, LLC Gamma-hydroxybutyrate compositions containing carbohydrate carriers
US8193211B2 (en) * 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate

Also Published As

Publication number Publication date
WO2006053186A3 (en) 2006-08-10
CN101098701A (zh) 2008-01-02
IL182906A0 (en) 2007-09-20
US20090137565A1 (en) 2009-05-28
CA2586975A1 (en) 2006-05-18
JP2008519847A (ja) 2008-06-12
KR20070085838A (ko) 2007-08-27
WO2006053186A2 (en) 2006-05-18
AU2005304352A1 (en) 2006-05-18
EP1809286A4 (en) 2010-09-01
EP1809286A2 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
MX2007005679A (es) Metodo para tratamiento de desordenes de movimiento.
MX2009002920A (es) Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
TW200735862A (en) Prostaglandin reductase inhibitors
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
HRP20080175T3 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
NO20054476D0 (no) Forbindelser for behandling av smerte
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
HK1114876A1 (en) Arthrospira-based compositions and uses thereof
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
MX2009002922A (es) Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico.
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
UA107562C2 (uk) Спосіб лікування псоріазу
HK1079526A1 (en) A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin
MX2009005351A (es) Compuestos utiles para tratar trastornos neurodegenerativos.
TW200600084A (en) Anti-coronavirus compounds
WO2004096237A3 (en) Phosphonate analogs for treating metabolic diseases
WO2008023003A8 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
NO20063320L (no) Anvendelse av gaboxadol for behandling av insomni

Legal Events

Date Code Title Description
FA Abandonment or withdrawal